These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 12050499)

  • 41. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
    Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
    J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased levels of IgG antibodies against peptides of the prostate stem cell antigen in the plasma of pancreatic cancer patients.
    Tanaka M; Komatsu N; Terakawa N; Yanagimoto Y; Oka M; Sasada T; Mine T; Gouhara S; Shichijo S; Okuda S; Itoh K
    Oncol Rep; 2007 Jul; 18(1):161-6. PubMed ID: 17549363
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
    Ito K; Yamamoto T; Miyakubo M; Takechi H; Ohi M; Shibata Y; Suzuki K
    J Urol; 2007 Oct; 178(4 Pt 1):1258-63; discussion 1263-4. PubMed ID: 17698107
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.
    Michael A; Stephan C; Kristiansen G; Burckhardt M; Loening SA; Schnorr D; Jung K
    Prostate; 2005 Jan; 62(1):34-9. PubMed ID: 15389818
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ; Kranse R; de Koning HJ; Schröder FH
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinical usefulness of the new criteria based on the serum quantification of prostate-specific antigen in the early diagnosis of prostatic cancer].
    Morote Robles J
    Actas Urol Esp; 1996 Jan; 20(1):1-12. PubMed ID: 8720993
    [No Abstract]   [Full Text] [Related]  

  • 47. Serum-autoantibodies for discovery of prostate cancer specific biomarkers.
    Massoner P; Lueking A; Goehler H; Höpfner A; Kowald A; Kugler KG; Amersdorfer P; Horninger W; Bartsch G; Schulz-Knappe P; Klocker H
    Prostate; 2012 Mar; 72(4):427-36. PubMed ID: 22012634
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [New biomarkers for prostate cancer].
    Suzuki H; Shimbo M; Ichikawa T
    Nihon Rinsho; 2005 Feb; 63(2):351-9. PubMed ID: 15714991
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serologic markers in prostate cancer.
    Harris D; Ruckle HC
    West J Med; 1996 Apr; 164(4):344-5. PubMed ID: 8732740
    [No Abstract]   [Full Text] [Related]  

  • 50. Expression of two testis-specific genes, SPATA19 and LEMD1, in prostate cancer.
    Ghafouri-Fard S; Ousati Ashtiani Z; Sabah Golian B; Hasheminasab SM; Modarressi MH
    Arch Med Res; 2010 Apr; 41(3):195-200. PubMed ID: 20682177
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early detection and monitoring of cancer with the anti-malignin antibody test.
    Abrams MB; Bednarek KT; Bogoch S; Bogoch ES; Dardik HJ; Dowden R; Fox SC; Goins EE; Goodfried G; Herrman RA
    Cancer Detect Prev; 1994; 18(1):65-78. PubMed ID: 8162608
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Profiling of antibody production against xenograft-released proteins by protein microarrays discovers prostate cancer markers.
    Jansen FH; van Rijswijk A; Teubel W; van Weerden WM; Reneman S; van den Bemd GJ; Roobol MJ; Bangma CH; Staal FJ; Jenster G
    J Proteome Res; 2012 Feb; 11(2):728-35. PubMed ID: 22136385
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Specificity of antibodies directed against Env protein of human endogenous retroviruses in patients with germ cell tumors.
    Sauter M; Roemer K; Best B; Afting M; Schommer S; Seitz G; Hartmann M; Mueller-Lantzsch N
    Cancer Res; 1996 Oct; 56(19):4362-5. PubMed ID: 8813125
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [An immunohistochemical study of prostate antigen using an enzyme-labeled antibody technique].
    Okano M; Deguchi T; Takeuchi T; Kuriyama M; Nishiura T
    Hinyokika Kiyo; 1983 Oct; 29(10):1369-71. PubMed ID: 6085712
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Circulating antibody to prostate antigen in patients with prostate cancer.
    Chu TM; Kuriyama M; Johnson E; Papsidero LD; Killian CS; Murphy GP; Wang MC
    Transplant Proc; 1984 Apr; 16(2):481-5. PubMed ID: 6202027
    [No Abstract]   [Full Text] [Related]  

  • 56. A simple test for detection of specific and unspecific immunological reactions in cancer.
    Ruíz Castañeda M
    Arch Invest Med (Mex); 1980; 11(1):83-93. PubMed ID: 7396635
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Studies on prostate specific antigen, gamma-seminoprotein (gamma-Sm) as a tumor marker of prostatic cancer].
    Kamachi S; Sakurabayashi I; Kawai T
    Rinsho Byori; 1984 Jul; 32(7):781-5. PubMed ID: 6389940
    [No Abstract]   [Full Text] [Related]  

  • 58. Prostate cancer: is an imperfect test worth the trouble?
    Consum Rep; 1997 Sep; 62(9):60-1. PubMed ID: 10182475
    [No Abstract]   [Full Text] [Related]  

  • 59. Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer.
    McNeel DG; Nguyen LD; Storer BE; Vessella R; Lange PH; Disis ML
    J Urol; 2000 Nov; 164(5):1825-9. PubMed ID: 11025777
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Basal cell-specific anti-keratin antibody 34betaE12: optimizing its use in distinguishing benign prostate and cancer.
    Ramnani DM; Bostwick DG
    Mod Pathol; 1999 May; 12(5):443-4. PubMed ID: 10349979
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.